Companies Dominating the Topical Androgen Receptor Inhibitors Market
- Cosmo Pharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Suzhou Kintor Pharmaceuticals Inc
- Sun Pharmaceutical Industries Limited
- Aranda Pharma Ltd
- Selleck Chemicals
Browse Key Market Insights with Data Illustration:
In the News
- Aug 2020- The U.S. FDA has approved the first-in-class androgen receptor inhibitor, carotene cream 1% (Winlevi, Cassiopea), for the treatment of acne vulgaris in individuals 12 years of age and older.
- Apr 2021- The National Medical Products Administration has given the green light for Kintor Pharmaceutical, a clinical-stage biotechnology company developing novel small molecule and biological therapeutics, to start GT20029 (gel/tincture) clinical trials for the treatment of androgenetic alopecia and acne.
- Nov 2023- The supplemental new drug application for XTANDI® has been approved by the U.S. Food and Drug Administration (FDA), as announced by Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. With this approval, XTANDI turns out the first and only androgen receptor signaling inhibitor authorized by the FDA for the management of patients with biochemically driven recurrence of nonmetastatic castration-sensitive prostate cancer (nmCSPC) who are at high risk of developing metastatic disease.
